You are here: Industry Insights > Tagrisso

News List

AZ’s Tagrisso brings ‘unprecedented’ benefit in untreated NSCLC pharmaphorum
April 17, 2018
AstraZeneca says its lung cancer drug Tagrisso has produced “unprecedented” survival benefit from first-line use in some patients with advanced disease.
Hanmi terminates lung cancer drug after being muscled out by AZ's Tagrisso pharmafile
April 16, 2018
South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it admits that circumstances within the space have meant that continued R&D costs would “eclipse its value”.
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cance worldpharmanews
December 19, 2017
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA)
AstraZeneca’s regulatory submission accepted for Tagrisso pharmaceutical-technology
December 01, 2017
The European Medicines Agency (EMA) has accepted AstraZeneca’s variation to the marketing authorisation application (MAAv) submission for Tagrisso (osimertinib) to treat patients with non-small-cell lung cancer (NSCLC).
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients w worldpharmanews
October 12, 2017
AstraZeneca announced that the US FDA)has granted Breakthrough Therapy Designation for Tagrisso for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer
AZ’ lung cancer drug Tagrisso bags breakthrough status pharmatimes
October 11, 2017
AstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway.
FDA grants breakthrough therapy designation to Tagrisso for NSCLC europeanpharmaceuticalreview
October 10, 2017
The FDA has granted Breakthrough Therapy Designation for Tagrisso for the 1st-line treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer…
AstraZeneca's Tagrisso beats standard of care in halting NSCLC pharmafile
September 12, 2017
AstraZeneca has revealed new data at the European Society of Medical Oncology on the efficacy of Tagrisso (osimertinib) in the first-line treatment of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer in adult patients.
AZ's Tagrisso continues successes with EU approval pharmafile
April 27, 2017
More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission...
Tagrisso (osimertinib) Receives FDA Full Approval drugs.com
April 06, 2017
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets...

Previous page 1 2 3 4 Next page